The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 11, 2020

Filed:

Jul. 15, 2015
Applicant:

Juno Therapeutics, Inc., Seattle, WA (US);

Inventors:

Kendall M. Mohler, Seattle, WA (US);

Hyam I. Levitsky, Seattle, WA (US);

Assignee:

Juno Therapeutics, Inc., Seattle, WA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/10 (2006.01); C12N 5/0783 (2010.01); C12N 15/12 (2006.01); C12N 15/11 (2006.01); A61K 39/00 (2006.01); A61K 38/17 (2006.01); C07K 16/30 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); C07K 16/40 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0638 (2013.01); A61K 39/00 (2013.01); A61K 39/0011 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 16/30 (2013.01); C07K 16/40 (2013.01); C12N 5/0636 (2013.01); C12Y 204/99 (2013.01); C12Y 207/07049 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01); C12N 2510/00 (2013.01);
Abstract

Provided are engineered cells for adoptive therapy, including NK cells and T cells. Also provided are compositions for engineering and producing the cells, compositions containing the cells, and methods for their administration to subjects. In some aspects, features of the cells and methods provide specificity and/or efficacy. In some embodiments, the cells contain genetically engineered antigen receptors that specifically bind to antigens, such as chimeric antigen receptors (CARs) and costimulatory receptors. In some embodiments, the cells include receptors targeting multiple antigens. In some embodiments, the cells include repression of one or more gene product, for example, by disruption of a gene encoding the gene product. In some embodiments, a gene encoding an antigen recognized by the engineered antigen receptor is disrupted, reducing the likelihood of targeting of the engineered cells.


Find Patent Forward Citations

Loading…